Home / Health / Wegovy Pill Promises Big Weight Loss & Better Mobility
Wegovy Pill Promises Big Weight Loss & Better Mobility
14 May
Summary
- Nearly 29% of obese patients lost over 10% weight early.
- Oral semaglutide improved mobility and physical function.
- Convenience of pills over injections aids long-term adherence.
A significant advancement in obesity treatment, the oral formulation of Wegovy (semaglutide 25 mg) has demonstrated substantial weight loss and improved physical functioning in patients. Findings from the OASIS 4 trial, presented at ECO 2026, revealed that approximately 28.8% of participants were 'early responders,' achieving at least 10% body weight reduction within 16 weeks, with an average loss of 21.6% by week 64.
Beyond weight reduction, the oral semaglutide significantly enhanced mobility and everyday physical capabilities. Participants reported nearly double the improvement in walking, standing, bending, and overall physical activity compared to a placebo group. This suggests benefits that extend beyond shedding pounds, positively impacting quality of life.
The convenience of oral medication is expected to boost patient adherence, a crucial factor in long-term weight management. Experts anticipate that oral GLP-1 receptor agonists like semaglutide will expand global access to obesity therapies, though medical supervision remains essential due to potential gastrointestinal side effects such as nausea and diarrhea.
